



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

20 May 2019

G MEDICAL'S NASDAQ PUBLIC OFFERING PROSPECTUS RELEASE

- H.C. Wainwright named as Underwriter and sole Running Manager of US Public Offering
- Offering to raise a minimum of US\$17M

Mobile and e-Health company **G Medical Innovations (ASX: GMV) ("G Medical" or the "Company")** is pleased to announce the United States Securities and Exchange Commission ("**SEC**") has approved the Company's Registration Statement on Form F-1 ("**Prospectus**") in relation to its public offering on the NASDAQ ("**US Public Offering**") of its American Depositary Shares ("**ADS**"). The Company intends to seek the listing of its ADS on the NASDAQ Capital Market under the symbol "GMVD".

H.C. Wainwright & Co., LLC has been named as Underwriter and sole Running Manager of US Public Offering.

The Prospectus is now public and the Company is proposing to undertake an equity capital raising to raise a minimum of US\$17M (with the Company having the ability to accept oversubscriptions).

The Executives of the Company will commence a US Roadshow on 3 June 2019, after the mandatory exposure period concludes. The number of shares proposed to be offered and sold, and the final amount proposed to be raised under the US Public Offering, will be finalised following completion of the US Roadshow.

In addition to the US Public Offering, Dr Yacov Geva, President and Chief Executive Officer, has, subject to the requisite shareholder approval, agreed to convert US\$2 million of loan funds he has advanced to the Company into ordinary shares in the Company (being further to his recently approved loan conversion of \$US3,317,500 to ordinary shares at the General Meeting of 24 April 2019).

The Company will remain listed on the Australian Stock Exchange and will be effectively dual listed on the NASDAQ on the completion of the US Public Offering.

A copy of the Prospectus will be available on the Company's website and on the SEC's website at https://www.sec.gov/Archives/edgar/data/1760764/000121390019009120/ff12019_gmedicalinnovat.htm.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of that jurisdiction.

About H.C. Wainwright

H.C. Wainwright & Co. is one of America's oldest and most trusted financial institutions.

H.C. Wainwright & Co. was founded in 1868 at the Union Bank Building in Boston, Massachusetts, located at the heart of the strongest financial center in post-Civil War America. Housed at 40 State Street in the same building as the Boston Stock Exchange, H.C. Wainwright & Co. had the advantage of crafting each line of business in-step with the financial landscape of the time. Furthermore, the firm's location on State Street,

where the activities of a thriving merchant port converged with the commerce of downtown Boston, provided a cutting-edge environment for experience and growth. Quickly becoming a prominent and respected member of the Exchange, H.C. Wainwright & Co.'s values of discipline, trust, and client stewardship set the company on a distinctly reputable trajectory towards financial stability and dependability.

Known from our inception as an honest, calculable, and reliable financial services firm, H.C. Wainwright & Co. is prepared and proud to be at our clients' side for generations to come. The values first instilled in us on State Street have never wavered and we continue to build upon our legacy of service in our new headquarters in New York City. Staffed by a diverse group of seasoned financiers, advisors, and researchers, H.C. Wainwright & Co. blends traditional values with innovative services, operating with care and integrity while offering leading-edge investment banking, corporate finance, and strategic advisory services to public and private growth companies across multiple sectors and regions.

According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate PIPE and RD transactions cumulatively since 1998.

Ends

Contact:

Corporate Advisors

Otsana Capital

108 Outram Street

West Perth WA 6005

Telephone: +61 8 9486 7244

www.otsana.com

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical Products

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital

signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.